Symons Julian A. 4
4 · Aligos Therapeutics, Inc. · Filed Mar 11, 2026
Research Summary
AI-generated summary of this filing
Aligos (ALGS) EVP/CSO Julian Symons Receives Award
What Happened Julian A. Symons, Executive Vice President and Chief Scientific Officer of Aligos Therapeutics (ALGS), received a grant of 23,310 derivative shares (transaction code A) on March 9, 2026. The award was granted at $0.00 per share (no cash paid) and is reported as a derivative award rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-03-09; Form 4 filed 2026-03-11 (appears timely under the 2-business-day rule).
- Award: 23,310 derivative shares granted at $0.00 per share (total reported value $0).
- Vesting: Footnote indicates 1/48th vests in equal monthly installments starting March 9, 2026; 100% vests on the fourth anniversary, subject to continued service.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Notes: This is a compensation/award grant (not a purchase or sale). No tax-withholding or disposition details were reported in the excerpt.
Context This award is a time-based equity grant that vests monthly over four years, a common retention/compensation structure for executives. Because it is an award (derivative) and not an open-market purchase, it does not represent an immediate cash investment by the insider nor an immediate sale of shares.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-03-09+23,310→ 23,310 totalExercise: $7.03Exp: 2036-03-09→ Common Stock (23,310 underlying)
Footnotes (1)
- [F1]1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.